Friday, 13 Jul 2018

You are here

Using Synovial Tissue Biopsies to Develop Precision Medicine for Rheumatoid Arthritis

Researchers at Northwestern University have used ultrasound-guided tissue biopsy from the joints to analyze the genes of tissue macrophages with the hope that transcriptional profiling of synovial macrophages may be correlated with clinical parameters or drug responsiveness in rheumatoid arthritis (RA) patients.(Citation source: https://buff.ly/2FPmgKA)

This attempt at precision medicine is driven by the "trial and error" approach to RA therapy, low response or incomplete response to very good drugs and evidence showing no correlations with blood sampling or clinical parameters.

This was a multi-site study of 41 rheumatoid arthritis patients who underwent US-guided synovial biopsies.

Participating sites included Northwestern University; the University of Alabama at Birmingham; Washington University, Columbia University, Mayo Clinic and University of Michigan.

Whole tissue samples from RA patients had a high degree of transcriptional heterogeneity. However,  the transcriptional profile of isolated RA synovial macrophages highlighted a subpopulation of patients and identified six novel transcriptional modules that were associated with disease activity and therapy. 

In the next phase of research, investigators will do pre- and post treatment (6 weeks later) biopsies to identify predictor gene sequence that will clearly identify which patients respond to a particular therapy.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The Diverse Fate of Seronegative Rheumatoid Arthritis

A Finnish Rheumatology Center followed 435 early, seronegative rheumatoid arthritis (RA) patients for 10-years and found that only 3% became erosive or seropositive RA. They also found that 32% could not be further reclassified, and that the remaining 65% evolve into another diagnosis, led by polymyalgia rheumatica (16%), psoriatic arthritis (11%), spondyloarthritis (9%), and osteoarthritis (10%).  

Does RA Have a Prodrome?

A pattern of increased primary care visits and joint complaints during the 2 years before rheumatoid arthritis (RA) was diagnosed were predictive of the diagnosis, a British case-control study found.

Can DMARDs Delay Rheumatoid Onset?

Preclinical rheumatoid arthritis (RA) is a hot new area wherein at risk individuals (seropositive, first degree relatives of RA patients, etc.) are being studied to assess the triggers that lead to progression to RA or whether therapies can be used to avert the onset of RA.

Seronegative and Seropositive Rheumatoids Respond Equally Well

A cohort study of 241 DMARD-naive rheumatoid arthritis (RA) patients, meeting either 1987 ACR or the 2010 ACR/EULAR  classification criteria for RA, compared the baseline status and long term outcomes of seronegative (SNRA) and seropositive (SPRA).

We Measure What we do in RA, But so What?

We are supposed to treat to a target (T2T) in RA. In other words, measure many components of the disease and its activity and calculate a score and if the patient is not in remission (or a low state if remission is not achievable) we are to make a treatment change.